Chromocell to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Chromocell Therapeutics (NYSE American: CHRO), a leader in non-opioid pain treatment development, will present at the H.C. Wainwright 26th Annual Global Investment Conference. CEO Frank Knuettel will provide a company overview, with the virtual presentation available from September 9th at 7:00 A.M. (ET).
Institutional investors can register at www.hcwevents.com/annualconference. The presentation will be accessible through Chromocell's Investor section website, with an archived replay available for at least 30 days. This event allows Chromocell to highlight its progress in developing innovative non-opioid pain treatments, focusing on modulating NaV1.7 receptors in the peripheral nervous system.
Chromocell Therapeutics (NYSE American: CHRO), leader nello sviluppo di trattamenti per il dolore non oppioidi, parteciperà alla 26ª Conferenza Annuale Globale di Investimento H.C. Wainwright. Il CEO Frank Knuettel fornirà una panoramica dell'azienda, con la presentazione virtuale disponibile dal 9 settembre alle 7:00 (ET).
Gli investitori istituzionali possono registrarsi su www.hcwevents.com/annualconference. La presentazione sarà accessibile tramite la sezione dedicata agli investitori del sito di Chromocell, con una replica archiviata disponibile per almeno 30 giorni. Questo evento consente a Chromocell di evidenziare i propri progressi nello sviluppo di trattamenti innovativi per il dolore non oppioidi, concentrandosi sulla modulazione dei recettori NaV1.7 nel sistema nervoso periferico.
Chromocell Therapeutics (NYSE American: CHRO), líder en el desarrollo de tratamientos para el dolor no opioides, presentará en la 26ª Conferencia Anual Global de Inversión H.C. Wainwright. El CEO Frank Knuettel ofrecerá una visión general de la empresa, con la presentación virtual disponible desde el 9 de septiembre a las 7:00 A.M. (ET).
Los inversores institucionales pueden registrarse en www.hcwevents.com/annualconference. La presentación será accesible a través de la sección de inversores del sitio web de Chromocell, con una repetición archivada disponible por al menos 30 días. Este evento permite a Chromocell destacar sus progresos en el desarrollo de tratamientos innovadores para el dolor no opioides, centrándose en la modulación de los receptores NaV1.7 en el sistema nervioso periférico.
크로모셀 테라퓨틱스 (NYSE American: CHRO)는 비오피오이드 통증 치료 개발의 선두주자로서 H.C. 웨인라이트 제26회 연례 글로벌 투자 컨퍼런스에 참석합니다. CEO 프랭크 크누텔이 회사 개요를 제공하며, 가상 발표는 9월 9일 오전 7:00 (ET)부터 доступно 합니다.
기관 투자자는 www.hcwevents.com/annualconference에서 등록할 수 있습니다. 발표는 크로모셀의 투자자 섹션 웹사이트를 통해 접근할 수 있으며, 아카이브된 재생은 최소 30일 동안 가능합니다. 이 행사는 크로모셀이 비오피오이드 통증 치료의 혁신 개발 진전을 강조할 수 있는 기회를 제공합니다. 말초 신경계에서 NaV1.7 수용체 조절에 중점을 두고 있습니다.
Chromocell Therapeutics (NYSE American: CHRO), leader dans le développement de traitements de la douleur non opioïdes, participera à la 26e Conférence Annuelle Mondiale d'Investissement H.C. Wainwright. Le PDG Frank Knuettel présentera un aperçu de l'entreprise, avec la présentation virtuelle disponible à partir du 9 septembre à 7h00 (ET).
Les investisseurs institutionnels peuvent s'inscrire sur www.hcwevents.com/annualconference. La présentation sera accessible via la section investisseurs du site de Chromocell, avec un replay archivé disponible pendant au moins 30 jours. Cet événement permet à Chromocell de mettre en avant ses progrès dans le développement de traitements innovants de la douleur non opioïdes, en se concentrant sur la modulation des récepteurs NaV1.7 dans le système nerveux périphérique.
Chromocell Therapeutics (NYSE American: CHRO), ein führendes Unternehmen in der Entwicklung von nicht-opioiden Schmerzbehandlungen, wird auf der 26. jährlichen globalen Investorenkonferenz von H.C. Wainwright präsentieren. CEO Frank Knuettel wird einen Unternehmensüberblick geben, wobei die virtuelle Präsentation ab 9. September um 7:00 Uhr (ET) verfügbar ist.
Institutionelle Investoren können sich unter www.hcwevents.com/annualconference registrieren. Die Präsentation wird über den Investorensektion der Chromocell-Website zugänglich sein, mit einer archivierten Wiederholung, die mindestens 30 Tage lang verfügbar ist. Diese Veranstaltung ermöglicht es Chromocell, die Fortschritte bei der Entwicklung innovativer nicht-opioider Schmerzbehandlungen hervorzuheben, mit einem Fokus auf die Modulation der NaV1.7-Rezeptoren im peripheren Nervensystem.
- None.
- None.
FREEHOLD, N.J., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corporation (“Chromocell”, or the “Company”), (NYSE American: CHRO), a pioneer in the development of non-opioid pain treatment therapeutics, today announced that it will be featured as a presenting company at the H.C. Wainwright 26th Annual Global Investment Conference.
Frank Knuettel, CEO of Chromocell, will provide an overview of the Company's business during the presentation. If you are an institutional investor, and would like to listen to the Company’s presentation, please click on the following conference registration link:
www.hcwevents.com/annualconference.
The virtual presentation will be available after September 9th, at 7:00 A.M. (ET).
Further, investors and interested parties can access a webcast of the presentation through the Investor section of Chromocell’s website. The Company will also provide an archived replay of the presentation, available for at least 30 days following the event.
This conference appearance offers an opportunity for Chromocell to showcase its progress and strategy in pioneering innovative non-opioid pain treatment therapeutics with a focus on modulating NaV1.7 receptors responsible for sensing and transmitting pain in the peripheral nervous system (“PNS”).
For more information about the conference or to schedule a one-on-one meeting, please visit H.C. Wainwright’s conference page here or alternatively reach out directly to your institutional salesperson.
About Chromocell
Chromocell Therapeutics Corporation is a clinical-stage biotechnology company focused on developing and commercializing novel, non-opioid, non-addictive therapeutics to alleviate pain and other associated medical conditions. The Company’s initial clinical focus is to selectively target the sodium ion-channel known as NaV1.7 for the treatment of various types of chronic neuropathic pain and acute and chronic eye pain. The Company’s portfolio also includes pre-clinical work on other sodium channel receptor subtypes, and the Company intends to explore these and other compounds for the treatment of additional pain indications. For company updates and to learn more about Chromocell, visit www.chromocell.com or follow us on social media.
Forward-Looking Statements
This press release contains forward-looking statements regarding the Company’s current expectations. These forward-looking statements include, without limitation, references to the Company’s expectations regarding (i) the amount of shares of Common Stock to be repurchased under the Repurchase Plan, if any, (ii) the Company’s belief that the trading price of its Common Stock does not reflect its clinical progress, (iii) the Company’s plans and ability to successfully develop and commercialize compounds, (iv) the Company’s belief that its portfolio of therapeutics will be suitable for neuropathic and chronic pain, (v) the Company’s plan and ability to successfully develop its intellectual properly independently or with partners, (vi) the Company’s ability to conduct repurchases in accordance with applicable laws and regulations, (vii) our ability to enhance stockholder value and (viii) the impact of laws and regulations. These statements are not guarantees of future performance and are subject to certain risks, uncertainties and assumptions that are difficult to predict.
Factors that could cause actual results to differ materially from those set forth in such forward-looking statements include, but are not limited to, risks and uncertainties related to (i) the Company expending its limited resources to pursue a compound or indication and failing to capitalize on different compounds or indications that may be more profitable or for which there is a greater likelihood of success and the Company potentially not being successful in discovering, developing and commercializing additional compounds, (ii) the Company needing to establish its market development capabilities to commercialize its products with the failure to do so potentially resulting in an inability to generate any revenue, (iii) there being no guarantee that the trading price of the Company’s Common Stock will be indicative of the Company’s clinical progress, and (iv) the Company’s ability to successfully develop its intellectual property and portfolio. These and other risks and uncertainties are described more fully in in our filings with the U.S. Securities and Exchange Commission. The information in this press release is provided only as of the date of this press release, and we undertake no obligation to update any forward-looking statements contained in this press release based on new information, future events, or otherwise, except as required by law.
For Investor Inquiries:
Mike Moyer
Managing Director, LifeSci Advisors, LLC
mmoyer@lifesciadvisors.com
FAQ
When is Chromocell (CHRO) presenting at the H.C. Wainwright Global Investment Conference?
Who will be presenting on behalf of Chromocell (CHRO) at the investment conference?
How can investors access Chromocell's (CHRO) presentation at the H.C. Wainwright conference?
What is the focus of Chromocell's (CHRO) research in pain treatment?
